BrainStorm Cell Therapeutics Shares Soar on Patent Wins

☀️Trending News

BRAINSTORM ($NASDAQ:BCLI): BrainStorm Cell Therapeutics, a global leader in developing autologous cellular therapies in the field of neurodegenerative diseases, has seen its stock soar after receiving major patents. The company’s shares have risen significantly on the news, providing a major boost to its market value. BrainStorm Cell Therapeutics is dedicated to developing novel autologous cellular therapies for the treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease. The company has developed a platform called NurOwn which utilizes their proprietary technology to expand autologous adult stem cells and then reintroduce them into the patient’s body. This process is believed to be effective in restoring lost neurological function.

The most recent patent wins from BrainStorm Cell Therapeutics will allow the company to expand their NurOwn platform, paving the way for further research and development in the field of neurodegenerative diseases. With the possibility of such groundbreaking treatments coming to fruition, investors have flocked to BrainStorm’s stock, driving its value up significantly. This move marks a major milestone for the company and could potentially be the beginning of a new era for those suffering from neurodegenerative disorders.

Price History

On Tuesday, shares of BRAINSTORM CELL THERAPEUTICS (BCT) soared 16.4% from its prior closing price of $0.2 to $0.2. BCT’s impressive gains can be attributed to multiple patent wins that are anticipated to aid the company’s progress in stem cell technology. The patents cover a range of applications, including developing and commercializing cellular therapies for neurological diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson’s disease.

BCT is currently in the midst of clinical trials of its NeuroCell product for ALS and the additional patent wins are expected to facilitate further development of this groundbreaking product. Investors have responded with enthusiasm, driving the stock price to its recent record high. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for BCLI. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for BCLI. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for BCLI. More…

Key Ratios Snapshot

Some of the financial key ratios for BCLI are shown below. More…

Analysis

As part of our analysis of BRAINSTORM CELL THERAPEUTICS’s wellbeing, we used our Star Chart to assess the company across various metrics. Our analysis shows that BRAINSTORM CELL THERAPEUTICS is strong in sales and market capitalization, but weak in asset, dividend, growth, and profitability. Our health score for BRAINSTORM CELL THERAPEUTICS was low at 2/10, which means this company is less likely to safely ride out any crisis without the risk of bankruptcy. We classified this company as an ‘elephant’, which means it is rich in assets after deducting off liabilities. Given BRAINSTORM CELL THERAPEUTICS’s strengths and weaknesses, we believe investors who are looking for a company with strong assets and sales performance would be interested in this company. Investors who are looking for rapid growth, high profitability, and high dividends may wish to look elsewhere. More…

Peers

The competition in the cell therapy market is heating up as more and more companies are vying for a piece of the pie. Among the major players are Brainstorm Cell Therapeutics Inc, TCR2 Therapeutics Inc, Adicet Bio Inc, and Iovance Biotherapeutics Inc. All of these companies are working on cutting-edge cell therapies that have the potential to change the way we treat diseases.

– TCR2 Therapeutics Inc ($NASDAQ:TCRR)

TCR2 Therapeutics Inc is a clinical-stage immuno-oncology company, which focuses on the development of novel T cell therapies for the treatment of cancer. The company has a market cap of $54.51M and a ROE of -24.78%. TCR2 is developing two novel T cell therapies, which are designed to target different types of cancer. The first therapy, which is in clinical trials, targets solid tumors, while the second therapy is in preclinical development and targets blood cancers.

– Adicet Bio Inc ($NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biopharmaceutical company focused on the development of immune cell therapies for cancer and other diseases. The company’s most advanced product candidate is a T cell therapy for solid tumors, which is currently in a Phase 1/2 clinical trial. The company has a market cap of $871.6M as of 2022 and a Return on Equity of -11.39%.

– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)

Iovance Biotherapeutics Inc is a late-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products based on tumor-infiltrating lymphocyte (TIL) technology.

The company’s lead product candidate, lifileucel, is a TIL therapy that is in Phase III clinical trials for the treatment of metastatic melanoma and recurrent or metastatic squamous cell carcinoma of the head and neck. Iovance is also evaluating lifileucel in a Phase II clinical trial for the treatment of cervical cancer.

Iovance has a market cap of 1.19B as of 2022. The company’s Return on Equity is -56.45%.

Summary

BrainStorm Cell Therapeutics is an Israeli biotechnology company that develops adult stem cell therapies for neurodegenerative diseases. As a result of their recent patent wins, the company’s stock price surged on the same day. This could be a good opportunity for investors to buy into the company in order to benefit from the potential gains associated with its promising research and development.

In-depth research and analysis should be conducted in order to properly evaluate the potential upside of such an investment. Investment in this particular company should be done with caution, as with any investment in a biotech company, as there are inherent risks associated with such investments.